Scientific Publications 2016 Kempf H, Olmer R, Haase A, Franke A, Bolesani E, Schwanke K, Robles-Diaz D, Coffee M, Göhring G, Dräger G, Pötz O, Joos TO, Martinez-Hackert E, Haverich A, Buettner FF, Ma

Was ist die beste Lizenz für Open-Access Veröffentlichungen und warum ist es CC-BY? Das DEAL-Konsortium startet eine Informationskampagne, um wissenschaftliche Autor*innen in Deutschland für die Bedeu

Concept and Aims Cardiovascular diseases, including myocardial infarction (MI), are the leading cause of pre-mature death worldwide, constituting a major socio-economic burden on the European and glob

Activities The research work in TECHNOBEAT is divided into 9 work packages (WPs) with a specific partner dedicated to lead respective WPs which reflects that partners’ area of expertise. Within TECHNO

Speakers Peter Andrews, University of Sheffield, UK Johann Bauersachs, Hannover Medical School, GER Nissim Benvenisty, The Hebrew University Jerusalem, ISR Paul Burridge, Feinberg School of Medicine,

Consortium structure and expertise The TECHNOBEAT consortium is particularly well-equipped to significantly impact on the enormous challenges ahead in hiPSC-based cell therapies, as it gathers a uniqu

Organising Committee Robert Zweigerdt Ulrich Martin Hannover Medical School, Germany Christine Mummery Leiden University Medical Center, NL Peter Andrews University of Sheffield, UK Joost Sluijter Uni

Programme Conference booklet NOW ONLINE! (PDF for download) Click here for topic titles and full list of speakers

iPS progeny production and the regulatory environment for cell therapies Sharing companies‘ perspectives and experience Safety risks and ethics in cell therapies Current State of the Art of iPS based